Omalizumab Shows Similar Early CSU Improvement to Remibrutinib

“By post hoc indirect comparison, improvements in disease activity appeared to be similar for omalizumab vs remibrutinib during the first 14 days post treatment initiation,” Joshi and colleagues wrote, according to a poster presented at the American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting.

New indirect analysis suggests that omalizumab and remibrutinib may offer comparable early relief for patients struggling with chronic spontaneous urticaria (CSU), HCPLive reported. The findings, shared in Phoenix, Arizona, compare the speed of symptom reduction between an established biologic therapy and a newer investigated agent.

While the comparison lacks the definitive clarity of a head-to-head clinical trial, the data provides a glimpse into how quickly these different mechanisms of action might stabilize a patient’s condition. For those living with the unpredictable and often debilitating skin welts of CSU, the timeline of relief is a critical factor in treatment selection.

Comparing rapid symptom relief

The investigation looked at how quickly patients achieved a clinical response, specifically measured by a weekly Urticaria Activity Score (UAS7) of 6 or less. In the pooled ASTERIA I/II data, omalizumab 300 mg showed significant early movement. By week 2, 39% of patients receiving the drug reached that response threshold, compared to just 6% in the placebo group.

The researchers then turned to an indirect comparison with remibrutinib, using pooled data from the phase 3 REMIX-1 and REMIX-2 trials. They utilized unmatched comparisons and 2-sample t tests to measure the placebo-adjusted differences in mean daily UAS between the two agents. The results indicated that the improvements did not differ significantly between the two drugs at the 2, 7, or 14-day marks.

Time Point	Omalizumab vs. Remibrutinib (P-value)
Day 2	P = .52
Day 7	P = .39
Day 14	P = .15

Post hoc analysis and demographic variations limit study comparisons

It is vital to approach these similarities with professional caution. The study was a post hoc analysis, meaning it was not the primary goal of the original trials, and it relied on unmatched cross-trial comparisons. This method does not account for the inherent differences between the specific patient populations involved in the separate studies.

There were also notable demographic variations between the groups. The omalizumab arm had a higher proportion of female patients at 76.9%, while the remibrutinib arms consisted of 67.7% and 65.7% female patients, respectively. The two sets of trials were conducted roughly a decade apart, which introduces variables regarding standard care and diagnostic consistency over time.

Funding and authorship also play a role in how this data is interpreted. The study was funded by Genentech, the manufacturer that markets omalizumab, and three of the six authors were Genentech employees. While the safety results for both drug programs had been published previously and were not reanalyzed, the commercial connection is a standard factor for clinicians to weigh when reviewing industry-funded research.

The clinical stakes for CSU patients

For the millions affected by chronic spontaneous urticaria, the “so what” of this data lies in the hope for rapid stabilization. CSU is more than just an itch; it is a condition that impacts sleep, work productivity, and overall mental health.

When a patient begins a new regimen, the speed at which they move from a high UAS7 score to a manageable level can dictate whether they stay on a treatment or seek alternatives.

The baseline data shows the severity of the condition being treated. Across the arms, mean UAS7 scores were consistently high, sitting between 30.2 and 30.6. Dermatology Life Quality Index scores, which measure the impact of the disease on daily life, ranged from 12.9 to 14.2.

The lack of a statistically significant difference in early improvements suggests that both pathways—the IgE-targeting approach of omalizumab and the BTK-inhibiting approach of remibrutinib—are hitting their targets with similar velocity in the first two weeks. However, without a direct head-to-head trial, doctors cannot yet say which is superior for long-term maintenance or specific patient phenotypes.

Omalizumab remains an effective treatment option for patients with CSU, according to the findings published by Joshi and colleagues.